Management of Localized Non-Small Cell Lung Cancer with EGFR Tumor Mutations with Dr Roy Herbst
EpisodeApr 12, 202139m
Dr Roy Herbst from the Yale Cancer Center discusses the clinical data on and optimal use of adjuvant osimertinib for patients with resected non-small cell lung cancer and an EGFR mutation.
CME information and select publications here.
Top comments